© 2023 BioMarin. All rights reserved.
Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|
Total Revenue | 2,096,039 | 1,846,275 | 1,860,461 | -- |
Cost of Revenue | 483,669 | 470,515 | 524,272 | -- |
Gross Profit | 1,612,370 | 1,375,760 | 1,336,189 | -- |
Operating Expenses | ||||
Research Development | 649,606 | 628,793 | 628,116 | -- |
Selling General and Administrative | 854,009 | 759,400 | 737,700 | -- |
Non Recurring | -- | -- | -- | -- |
Others | 67,193 | 61,900 | 62,200 | -- |
Total Operating Expenses | 1,570,808 | 1,450,093 | 1,428,016 | -- |
Operating Income or Loss | 41,562 | (74,333) | (91,827) | -- |
Income from Continuing Operations | ||||
Total Other Income/Expenses Net | 105,950 | 3,846 | 62,137 | -- |
Earnings Before Interest And Taxes | 164,953 | (60,606) | (13,013) | -- |
Interest Expense | 15,377 | 14,744 | 29,309 | -- |
Income Before Tax | 149,576 | (75,350) | (42,322) | -- |
Income Tax Expense | 8,015 | (11,270) | (901,422) | -- |
Minority Interest | -- | -- | -- | -- |
Net Income From Continuing Ops | 141,561 | (64,080) | 859,100 | -- |
Non-recurring Events | ||||
Discontinued Operations | -- | -- | -- | -- |
Extraordinary Items | -- | -- | -- | -- |
Effect Of Accounting Changes | -- | -- | -- | -- |
Other Items | 0 | 0 | 0 | -- |
Net Income | 141,561 | (64,080) | 859,100 | -- |
Preferred Stock And Other Adjustments | -- | -- | -- | -- |
Net Income Applicable To Common Shares | 141,561 | (64,080) | 859,100 | -- |